These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29269661)

  • 21. BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome.
    Perico L; Mandalà M; Schieppati A; Carrara C; Rizzo P; Conti S; Longaretti L; Benigni A; Remuzzi G
    Am J Kidney Dis; 2017 Jul; 70(1):145-150. PubMed ID: 28242136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guillain-Barré syndrome in a patient with renal cell carcinoma following the first course of pazopanib therapy.
    Koshikawa H; Tsukie T; Kurita A; Fujikura M; Suzuki M; Araki K
    J Infect Chemother; 2017 Nov; 23(11):798-799. PubMed ID: 28506529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib.
    Jacobs C; Kim DW; Straka C; Timmerman RD; Brugarolas J
    J Clin Oncol; 2013 Mar; 31(7):e114-7. PubMed ID: 23319695
    [No Abstract]   [Full Text] [Related]  

  • 24. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome.
    Koshikawa M; Mukoyama M; Mori K; Suganami T; Sawai K; Yoshioka T; Nagae T; Yokoi H; Kawachi H; Shimizu F; Sugawara A; Nakao K
    J Am Soc Nephrol; 2005 Sep; 16(9):2690-701. PubMed ID: 15987752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.
    Duffaud F; Sleijfer S; Litière S; Ray-Coquard I; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla SP; Dewji R; Marreaud S; Verweij J; van der Graaf WT
    Eur J Cancer; 2015 Nov; 51(17):2615-23. PubMed ID: 26321011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
    Maráz A; Bodrogi I; Csejtei A; Dank M; Géczi L; Küronya Z; Mangel L; Petrányi A; Szûcs M; Bodoky G
    Magy Onkol; 2013 Sep; 57(3):173-6. PubMed ID: 24107823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pazopanib, a new therapy for metastatic soft tissue sarcoma.
    Verweij J; Sleijfer S
    Expert Opin Pharmacother; 2013 May; 14(7):929-35. PubMed ID: 23488774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pazopanib. Kidney cancer: many risks, but is there a benefit for patients?
    Prescrire Int; 2011 Mar; 20(114):64-6. PubMed ID: 21648224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteinuria with first-line therapy of metastatic renal cell cancer.
    Land JD; Chen AH; Atkinson BJ; Cauley DH; Tannir NM
    J Oncol Pharm Pract; 2016 Apr; 22(2):235-41. PubMed ID: 25505255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile.
    Pal SK; Hossain DM; Zhang Q; Frankel PH; Jones JO; Carmichael C; Ruel C; Lau C; Kortylewski M
    J Urol; 2015 Apr; 193(4):1114-21. PubMed ID: 25286010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective effects of tadalafil on damaged podocytes in an adriamycin-induced nephrotic syndrome model.
    Tomita N; Hotta Y; Naiki-Ito A; Sanagawa A; Kataoka T; Furukawa-Hibi Y; Takahashi S; Kimura K
    J Pharmacol Sci; 2022 Jun; 149(2):53-59. PubMed ID: 35512855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
    Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
    BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report.
    Yamada R; Okawa T; Matsuo K; Suzuki M; Mori N; Mori K
    BMC Nephrol; 2019 Jan; 20(1):14. PubMed ID: 30634936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats.
    Fujimura T; Yamagishi S; Ueda S; Fukami K; Shibata R; Matsumoto Y; Kaida Y; Hayashida A; Koike K; Matsui T; Nakamura K; Okuda S
    Nephrol Dial Transplant; 2009 May; 24(5):1397-406. PubMed ID: 19042927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database.
    Hackshaw MD; Nagar SP; Parks DC; Miller LA
    J Manag Care Spec Pharm; 2014 Jun; 20(6):603-10. PubMed ID: 24856598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M; He CS; Huang JK; Lin QZ
    Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An autopsy case of severe acute pancreatitis induced by administration of pazopanib following nivolumab.
    Tanaka T; Sakai A; Shiomi H; Masuda A; Kobayashi T; Tanaka S; Nakano R; Shigeoka M; Koma YI; Kodama Y
    Pancreatology; 2021 Jan; 21(1):21-24. PubMed ID: 33184007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer.
    Altorki N; Lane ME; Bauer T; Lee PC; Guarino MJ; Pass H; Felip E; Peylan-Ramu N; Gurpide A; Grannis FW; Mitchell JD; Tachdjian S; Swann RS; Huff A; Roychowdhury DF; Reeves A; Ottesen LH; Yankelevitz DF
    J Clin Oncol; 2010 Jul; 28(19):3131-7. PubMed ID: 20516450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.
    Keir ST; Morton CL; Wu J; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2012 Sep; 59(3):586-8. PubMed ID: 22190407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.